Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 22, 2024
Product Development

Newco trend watch: Clusters of launches point to areas undergoing derisking

Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | May 21, 2024
Emerging Company Profile

Crossbow: Tumor antigen targeting beyond cell surface proteins, at scale

Through antibody targeting of HLA-peptide complexes, the MPM-built biotech is turning intracellular tumor antigens into handles for T cell engagers
BioCentury | Jan 27, 2017
Clinical News

Defitelio: Ph III started

BioCentury | Jun 1, 2015
Clinical News

CX-01: Phase I data

BioCentury | Mar 20, 2014
Distillery Therapeutics

Indication: Various

BioCentury | Apr 8, 2013
Clinical News

Defibrotide: Phase I started

BioCentury | Dec 20, 2010
Clinical News

Defibrotide: Expanded access program interim data

BioCentury | Sep 2, 2010
Distillery Therapeutics

Indication: Cardiovascular disease

BioCentury | Feb 14, 2005
Clinical News

PGX-100: Start Phase I

Items per page:
1 - 9 of 9
Help Center
Username
Request a Demo
Request Training
Ask a Question